Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Vector Borne Dis ; 2024 May 20.
Article in English | MEDLINE | ID: mdl-38842531

ABSTRACT

BACKGROUND OBJECTIVES: Scrub typhus is clinically undifferentiated from other aetiologies for acute febrile illness such as enteric fever, dengue, malaria, and leptospirosis. Rapid ELISA tests are being used as an alternative to immunofluorescence assay in tropical countries. METHODS: In this study, we compared and evaluated commercially available InBios Scrub Typhus Detect IgM Rapid Test (USA) for diagnosing human scrub typhus infection using archived and prospectively collected samples against the reference standard, InBios Scrub Typhus Detect IgM ELISA (USA). RESULTS: The data analysis of archived samples on rapid test revealed a moderate sensitivity of 53.92% and a specificity of 100%. Meanwhile, prospective serum samples demonstrated higher sensitivity and specificity of 96.4% and 94.6%, respectively. INTERPRETATION CONCLUSION: The InBios Scrub Typhus Detect IgM rapid test can be a good point-of-care assay during surveillance, outbreak investigations, and case identification.

2.
J Med Virol ; 96(2): e29427, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38288882

ABSTRACT

Influenza virus is known to cause mild to severe respiratory infections and is also prone to genetic mutations. Of all the mutations, neuraminidase (NA) gene mutations are a matter of concern, as most approved antivirals target this protein. During the 2020 influenza season, an emergence of mutation in the NA gene, affecting the binding of the World Health Organization (WHO)-recommended probes to the specific site of the NA gene, was reported by our group. As a result of this mutation, the WHO-recommended allelic discrimination real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay was unable to detect wild-type (H275) or mutant oseltamivir-resistant (Y275) strains of influenza A(H1N1)pmd09 viruses. In the current study, the WHO-recommended probes were redesigned according to the mutation in the probe binding site. Fifty undetermined samples (2020-2021) from the previous study were retested with the newly designed probes and found to be positive for H275 and/or Y275. The results obtained were similar to the Sanger sequencing results from the previous study, suggesting that the redesigned probes were efficient in discriminating between wild-type and mutant-type viruses. Furthermore, 133 samples from 2022, making a total of 183 samples (2020-2022), were tested using improved allelic discrimination real-time RT-PCR, and the overall prevalence rate of oseltamivir resistance in 2020-2022 was found to be 0.54%.


Subject(s)
Influenza A Virus, H1N1 Subtype , Influenza, Human , Humans , Oseltamivir/pharmacology , Oseltamivir/therapeutic use , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Influenza A Virus, H1N1 Subtype/genetics , Reverse Transcriptase Polymerase Chain Reaction , Mutation, Missense , Viral Proteins/genetics , Drug Resistance, Viral/genetics , Mutation , Neuraminidase/genetics
3.
J Med Virol ; 95(5): e28764, 2023 05.
Article in English | MEDLINE | ID: mdl-37212286

ABSTRACT

Influenza viruses can mutate genetically and cause a range of respiratory ailments. The H275Y mutation in the neuraminidase (NA) gene reduces the effectiveness of oseltamivir, a widely used drug for the treatment of Influenza A and B virus infection. The World Health Organization (WHO) recommends single-nucleotide polymorphism assays to detect this mutation. The present study aims to estimate the prevalence of H275Y mutation conferring oseltamivir resistance in Influenza A(H1N1)pdm09 virus among hospitalized patients from June 2014 to December 2021. Following the WHO protocol, allelic discrimination real-time RT-PCR was performed for 752 samples. Out of the 752 samples, 1 tested positive for Y275 gene mutation by allelic discrimination real-time RT-PCR. In samples of years 2020 and 2021, neither the H275 nor Y275 genotype was detected. Sequencing of the NA gene of all negative samples showed a mismatch between the NA sequence and the probes used in the allelic discrimination assay. Also, Y275 mutation was detected in only 1 sample from 2020. The prevalence of oseltamivir resistance was estimated as 0.27% among the Influenza A(H1N1)pdm09 patients during 2014-2021. The study highlights that the WHO-recommended probes for detecting H275Y mutation may not be useful to detect 2020 and 2021 circulating strains of Influenza A(H1N1)pdm09, emphasizing the need for continuous monitoring of mutations in the influenza virus.


Subject(s)
Influenza A Virus, H1N1 Subtype , Influenza A virus , Influenza, Human , Humans , Oseltamivir/pharmacology , Oseltamivir/therapeutic use , Influenza, Human/drug therapy , Influenza, Human/epidemiology , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Influenza A Virus, H1N1 Subtype/genetics , Reverse Transcriptase Polymerase Chain Reaction , Mutation, Missense , Mutation , Influenza A virus/genetics , Neuraminidase/genetics , Drug Resistance, Viral/genetics
4.
Trop Med Infect Dis ; 7(6)2022 Jun 19.
Article in English | MEDLINE | ID: mdl-35736988

ABSTRACT

The COVID-19 pandemic and public health response to the pandemic has caused huge setbacks in the management of other infectious diseases. In the present study, we aimed to (i) assess the trends in numbers of samples from patients with influenza-like illness and severe acute respiratory syndrome tested for influenza and the number and proportion of cases detected from 2015−2021 and (ii) examine if there were changes during the COVID-19 period (2020−2021) compared to the pre-COVID-19 period (2015−2019) in three states of India. The median (IQR) number of samples tested per month during the pre-COVID-19 period was 653 (395−1245), compared to 27 (11−98) during the COVID-19 period (p value < 0.001). The median (IQR) number of influenza cases detected per month during the pre-COVID-19 period was 190 (113−372), compared to 29 (27−30) during the COVID-19 period (p value < 0.001). Interrupted time series analysis (adjusting for seasonality and testing charges) confirmed a significant reduction in the total number of samples tested and influenza cases detected during the COVID-19 period. However, there was no change in the influenza positivity rate between pre-COVID-19 (29%) and COVID-19 (30%) period. These findings suggest that COVID-19-related disruptions, poor health-seeking behavior, and overburdened health systems might have led to a reduction in reported influenza cases rather than a true reduction in disease transmission.

5.
Sci Rep ; 11(1): 17118, 2021 08 24.
Article in English | MEDLINE | ID: mdl-34429443

ABSTRACT

Kyasanur forest disease virus (KFDV) causing tick-borne hemorrhagic fever which was earlier endemic to western Ghats, southern India, it is now encroaching into new geographic regions, but there is no approved medicine or effective vaccine against this deadly disease. In this study, we did in-silico design of multi-epitope subunit vaccine for KFDV. B-cell and T-cell epitopes were predicted from conserved regions of KFDV envelope protein and two vaccine candidates (VC1 and VC2) were constructed, those were found to be non-allergic and possess good antigenic properties, also gives cross-protection against Alkhurma hemorrhagic fever virus. The 3D structures of vaccine candidates were built and validated. Docking analysis of vaccine candidates with toll-like receptor-2 (TLR-2) by Cluspro and PatchDock revealed strong affinity between VC1 and TLR2. Ligplot tool was identified the intermolecular hydrogen bonds between vaccine candidates and TLR-2, iMOD server confirmed the stability of the docking complexes. JCAT sever ensured cloning efficiency of both vaccine constructs and in-silico cloning into pET30a (+) vector by SnapGene showed successful translation of epitope region. IMMSIM server was identified increased immunological responses. Finally, multi-epitope vaccine candidates were designed and validated their efficiency, it may pave the way for up-coming vaccine and diagnostic kit development.


Subject(s)
Encephalitis Viruses, Tick-Borne/immunology , Epitopes/chemistry , Kyasanur Forest Disease/prevention & control , Molecular Docking Simulation , Viral Envelope Proteins/immunology , Viral Vaccines/immunology , B-Lymphocytes/immunology , Epitopes/immunology , HLA-DR Antigens/chemistry , HLA-DR Antigens/immunology , Humans , T-Lymphocytes/immunology , Toll-Like Receptor 2/chemistry , Toll-Like Receptor 2/metabolism , Viral Envelope Proteins/chemistry , Viral Vaccines/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...